Tyme to Present at Biotech Showcase™ 2018

NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq: TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present a company overview at the Biotech Showcase™ 2018, to be held Jan. 8-10, 2018.

Biotech Showcase 2018 Location: San Francisco, Calif.Presentation date / time: Wednesday, Jan. 10, 2018, 4:30 p.m. PST

About Tyme Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and the Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer.

For more information about Tyme, visit www.tymeinc.com.

Contacts

Tyme Inc.Jonathan EckardChief Scientific Affairs Officer[email protected]

ICR HealthcareInvestorsStephanie Carrington[email protected]646-277-1282

6 DegreesMediaSarah Hall[email protected] 215-313-5638

Source: Tyme Technologies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CougarD Unveils Major Update: Revolutionary Innovation
• ValueAct Announces Support for the Substantial Changes in Strategy and Board Leadership Announced by Seven & i
• Centamin PLC Announces Q1 2024 Report